Clinical Trial Detail

NCT ID NCT03138512
Title A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma (CheckMate 914)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

renal cell carcinoma

clear cell renal cell carcinoma

Therapies

Ipilimumab + Nivolumab

Age Groups: adult senior

No variant requirements are available.